Endometrial cancer cell lines are sensitive to paclitaxel

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 475-480

  Rantanen, Virpi ^a   Grénman, Seija ^a   Kulmala, Jarmo ^a   Grénman, Reidar ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemosensitivity; Endometrial carcinoma; In vitro assay; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0029932107     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
2. Long BF and Fairchild CR: Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54: 4355-4361, 1994.
3. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi GN: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
4. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Cross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH and Hong WK: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384388, 1993.
5. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R and Arbuck SG: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1.000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 11: 2405-2410, 1993.
6. Forastiere AA: Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck Semin Oncol 20(Suppl. 3): 56-60, 1993.
7. Seski JC, Edwards CL, Herson J and Rutledge FN: Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 59: 225-228, 1982.
8. Green III JB, Green S, Alberts DS, O'Toole R, Surwit EA and Noltimier JW: Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 75: 696-700, 1990.
9. Pasmantier MW, Coleman M, Silver RT, Mamaril AP, Quiguyan CC and Galindo Jr AG: Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep 69: 539-542, 1985.
10. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE and Davidson M: A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer. Proc Am Soc Clin Oncol 12: A808, 1993.
11. Maguire YP, Lieu KL and Bartels P: In Vitro test for fresh human tumours to Taxol. Proc Am Assoc Cancer Res 34: A581, 1993.
12. Untch M, Untch A, Sevin B-U, Angioli R, Perra JP, Koechli O and Averette HE: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anti-Cancer Drugs 5: 24-30, 1994
13. Rantanen V, Grenman S, Kulmala J and Grenman R: Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482486, 1994
14. Way DL, Grosso DS, Davis JR, Surwit EA and Christian CD: Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In vitro 19: 147-158, 1983.
15. Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP and Bradley FM: KLE: A cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol 17: 213-230, 1984.
16. Grenman SE, Van Dyke DL, Worsham MJ, Del Rosario F, Roberts JA, McClatchey KD, Schwartz DR, Babu VR and Carey TE: UM-EC-1, a new hypodiploid human cell line derived from a poorly differentiated endometrial cancer. Cancer Res 48: 1864-1873, 1988.
17. Grenman SE, Worsham MJ, Van Dyke DL, England B, McClatchey KD, Babu VR, Roberts JA, Maenpaa J and Carey TE: Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecol Oncol 37: 188-199, 1990.
18. Rantanen V, Grénman S, Kulmala J, Jaakkola M, Lakkala T, Sajantila A, Klemi P and Grenman R: Characterization and radiosensitivity of UT-EC-2A and UT-EC-2B, two new highly radiosensitive endometrial cancer cell lines derived from a primary and metastatic tumour of the same patient. Gynecol Oncol 56: 53-62, 1995.
19. Rantanen V, Grenman S, Kulmala J, Alanen K, Lakkala T and Grenman R: Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay. J Cancer Res Clin Oncol 120: 712-716, 1994.
20. Grénman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
21. Massad LS, Williams S and Mutch DG: Cell lines derived from endometrial cancers are resistant to lysis by Taxol. Gynecol Oncol 49: 131-132, 1993.
22. Shinohara K and Nakano H. Interphase death and reproductive death in X-irradiated MOLT-4 cells. Radiat Res 135: 197-205, 1993.
23. Jaakkola M, Rantanen V, Grénman S, Kulmala J and Grenman R: Vulvar squamous cell carcinoma is sensitive to Paclitaxel in vitro. 1996 (submitted).
24. Engblom P, Rantanen V, Kulmala J and Grénman S: Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well ptate clonogenic assay. 1996 (submitted).
25. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winogard B and Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
26. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE and Reed E: Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24, 1994.
27. Kelland LR and Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450, 1992.
28. Untch M, Sevin B-U, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O and Averette HE: Evaluation of Paclitaxel (Taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53: 44-49, 1994.
29. Horwitz SB, Rao S, Yang C-PH and Orr GA: Mechanisms of resistance. In: Paclitaxel in Cancer Treatment (McGuire WP and Rowinsky EK, eds). New York, Marcel Dekkel Inc, 1995, pp 45-54.
30. Kirsten F, Atkinson KH, Coppleson JVM, Elliott PM, Green D, Houghton R, Murray JC, Russell P, Solomon HJ, Friedlander M, Swanson CE and Tattersall MHN. Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynecol 94: 583-588, 1987.
31. Kelland LR and Tonkin KS :In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity. Eur J Cancer Clin Oncol 25: 1211-1218, 1989.